Opioid Pain Articles & Analysis
19 news found
A new study published in Proceedings of the National Academy of Sciences (PNAS) indicates, “Delta opioid receptors have a built-in mechanism for pain relief and can be precisely targeted with drug-delivering nanoparticles, making them a promising target for treating chronic inammatory pain with fewer side eects.” Researchers used ...
Certain buprenorphine medicines prescribed to treat opioid use disorder (“OUD”) and pain have been recently associated with numerous serious oral health problems requiring medical intervention. ...
Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatment Over 142 million opioid prescriptions dispensed in the U.S. in 20201 More than 1.7 million people in the U.S. suffered from substance use disorders related to prescription opioid pain relievers in ...
DEA’s National Prescription Drug Take Back Day reflects DEA’s commitment to Americans’ safety and health, encouraging the public to remove unneeded medications from their homes as a measure of preventing medication misuse and opioid addiction from ever starting. The Berkshire team supports the DEA’s commitment to making communities safer and healthier. ...
The initial intended use for COPA will include the delivery of opioids for the treatment of chronic pain and the delivery of methadone in Medication Assisted Therapy for the treatment of opioid use disorder. ...
The Company intends to initially seek opportunities to leverage COPA in the delivery and remote management of controlled oral liquid medications for chronic pain and opioid addiction medication assisted therapy, as the Company believes they have the greatest need for the benefits of COPA’s features. ...
There is a high unmet medical need in chronic pain, particularly among patients with concomitant opioid use problems. If approved, Buvidal could become an important therapeutic option for the management of chronic pain, adding to the current indication of treating opioid dependence”, says Dr. ...
The pharmacokinetic profile of QIXLEEF™ is well indicated to help manage short episodes of pain such as breakthrough pain and will offer patients and physicians a viable, safer, and non-opioid option for pain management." ...
Three overarching features combine to make the COPA technology unique: security, compliance support (metrics) with remote monitoring and precise liquid dispensing. Chronic pain and opioid addiction medication assisted therapy have been identified as potential indications with the greatest need for the benefits of these features. ...
“We applaud those dedicated to raising awareness of the global overdose and addiction crisis as we all grapple with the challenges associated with pain medication, including the dangers of misuse, abuse and diversion of medications," said John Timberlake, Chief Executive Officer of Berkshire Biomedical. ...
With his help, the technology we're developing with Stevanato Group has great potential for application beyond our non-opioid BB106 therapy for pain management," said Jeffrey Becker, co-founder and CSO, Bexson Biomedical. ...
Bexson Biomedical, Inc., a research-stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, announced today that they closed a $4.8 million Series A round of financing. Funding will support the company through pre-clinical and GMP manufacturing scale up for its proprietary ketamine formulation, BB106, and the development of a wearable ...
(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HF10® therapy for patients with chronic pain. ...
The study showed significant improvements in time to ambulation, total post-procedure time and time-to-discharge eligibility, as well as improved patient satisfaction scores and significantly reduced use of opioid pain medications. Principal investigators and authors of the study include Andrea Natale, M.D., of the Texas Cardiac Arrhythmia Institute; Mintu ...
Under the agreement, the parties will work together to obtain appropriate regulatory approvals and commercialize self-contained, infusible, non-opioid post-operative pain pharmaceutical product in the United States, Canada and Mexico. ...
The study showed significant improvements in time to ambulation, total post-procedure time and time-to-discharge eligibility, as well as improved patient satisfaction scores and reduced use of opioid pain medications. Results of the trial were presented at the 2018 AHA Scientific Sessions by Andrea Natale, M.D., co-principal investigator and executive medical ...
AMBULATE demonstrated that patients in the VASCADE MVP arm had significantly improved patient satisfaction and a significant reduction in the post-procedure use of opioid pain medications. Late-breaking results were presented at the American Heart Association 2018 Scientific Sessions. ...
Sana Health, a medical technology startup based in Boulder, Colo., is developing a non-invasive neuromodulation device that integrates a heart rate variability sensor for personalized chronic pain management. “It is a true honor to be recognized by the medtech community in this way, particularly given the other incredible finalists in the competition. The funding from this ...
MM-II is a novel non-opioid product that leverages the physical properties of proprietary liposomes to lubricate arthritic knee joints, thereby reducing friction and wear, consequently leading to joint pain reduction. ...